Published on February 21, 2014
The future of drug discovery has arrived Reducing development time, cost & risk Investor Presentation | March 2014
Disclaimer When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forwardlooking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. TSXV: COT 2
Critical Outcome Technologies Inc. A bioinformatics and accelerated drug discovery company Listed on the TSX-V under the symbol COT since 2006 TSXV: COT 3
Investment highlights 1 2 Potential cancer breakthrough drug candidate is nearly Phase 1 ready 3 TSXV: COT We reduce the time, cost & risk of bringing new drugs to market We have many more revenue opportunities in our pipeline 4
Conventional drug development is a long & expensive process characterized by a high risk of failure TSXV: COT 11 – 15 years $1 billion or more 1 FDA approval 5
What we do Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs. Saving significant $$$ Increasing revenue period under patent protection TSXV: COT 6
How we do it – CHEMSAS® Proprietary, artificial intelligence based drug discovery platform technology TSXV: COT 7
Advantages of CHEMSAS® Computational replication of traditional ‘wet lab’ drug discovery process TSXV: COT Failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’ Higher probability of clinical & commercial success 8
Potential cancer breakthrough Our lead compound, COTI-2, is effective against cancers with mutations of the p53 gene TSXV: COT 9
Why COTI-2 is exciting > 50% of all human cancers have a p53 mutation (eg. ~ 95% of ovarian cancers) Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013) Novel, first-in-class Strong IP protection in place TSXV: COT 10
COTI-2 is (nearly) Phase 1 ready In final 2-species toxicity studies – completion in first half of 2014 FDA IND filing expected in second half of 2014 (leading to Phase 1 clinical trial) Pursuing orphan drug and/or breakthrough therapy status Signed an LOI with a strategic partner, Portage Biotech Inc., for clinical development TSXV: COT 11
COTI-2 = significant revenue potential Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1): Upfront payments of approx. $25-$92 million Milestone payments between $550-$1,100 million Royalties on net sales 1st half of 2013 (2) – 16 Phase 1 licensing deals with 6 in cancer – avg. upfront $30m TSXV: COT (1) (2) Medius Associates Thomson Reuters 12
Other revenue opportunities Robust internal pipeline of compounds - AML, colorectal cancer, small cell lung cancer library, MS, etc. 3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015 - Western University - Delmar Chemicals - Major Pharma Co. TSXV: COT 13
Looking ahead Other CHEMSAS® applications: CHEMFirm – Small molecule profiling & investment due diligence tool Drug library profiling – Based on customer identified criteria Drug repurposing – Finding new purposes for drugs coming off patent TSXV: COT 14
Project ROSALIND Programmable computer simulation of human cancer cell signaling Better personalized treatment decisions based on genetic profile of one’s cancer Personalized cancer gene profiling projected to be * ~ $35B market by 2018 TSXV: COT * Markets and Markets (2013) 15
Summary 1 2 Potential cancer breakthrough drug candidate is nearly Phase 1 ready 3 TSXV: COT We reduce the time, cost & risk of bringing new drugs to market We have many more revenue opportunities in our pipeline 16
The future of drug discovery has arrived Reducing development time, cost & risk Dr. Wayne Danter President & CEO Tel: (519) 858-5157 email@example.com www.criticaloutcome.com www.facebook.com/criticaloutcome twitter.com/criticaloutcome www.slideshare.net/criticaloutcome
March 2016. 2 This presentation ... performance or achievements of Critical Outcome ... this presentation or the disclosure of its contents to anyone ...
Investor Presentation March 2014 www.alembic-india.com BSE: ... Critical Care ALCARE MEGACARE ... ORG March, 2014 Gestofit Gynecology 284
Investors. Results and Presentations; Annual ... Results for year ended 31 March 2014: ... acquisition of Avincis Mission Critical Services: 21 Mar 2014:
PDAC Presentation: 09-Mar-2016: Uranium: Critical to a clean energy future: 03-Dec-2015: ... 17-Apr-2014: PDAC Investor Presentation – March 2014 ...
March 10, 2014. 2 Certain statements ... presentation represent WestJet’s expectations as of the date of this presentation and are subject to change ...
2014; 2013; 2012; Financials ... Investors. Targeted Therapeutics. Targeted ... Critical Outcome Technologies Appoints Experienced Industry Executive as ...
SHAREHOLDER CONTACTS. Investor Relations Manager: Microgen plc Old Change House 128 Queen Victoria Street London EC4V 4BJ United Kingdom Email: investors@ ...
Investor Day 10 December 2014 ... risks and uncertainties” of Glencore’s Annual Report 2013 and “Risks and uncertainties” in Glencore’s 2014 ...